All Hail Biopharma Market Performance
The first half of the year after a presidential election has meant losses for biopharma indices in the last three election cycles. On the heels of a year of strong performance for the sector, can momentum hold into 2013?
You may also be interested in...
Higher valuations, better quality companies, improved aftermarket performance and a broadening investor pool are all conspiring to advance the state of biotech IPOs. But VCs continue to see little step-up at IPO.
If demand-side pressures on the life science sector were not enough, generic price erosion, debt repayment and extended restructurings are worsening the generic pharmaceutical investment proposition.
California state Attorney General Xavier Becerra promised during two US Senate committee hearings that, if confirmed as Secretary of Health and Human Services, he will let science shape HHS policy.